These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34055932)

  • 1. Machine Learning for Predicting Heart Failure Progression in Hypertrophic Cardiomyopathy.
    Fahmy AS; Rowin EJ; Manning WJ; Maron MS; Nezafat R
    Front Cardiovasc Med; 2021; 8():647857. PubMed ID: 34055932
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical characteristics and outcome of end stage hypertrophic cardiomyopathy: Role of age and heart failure phenotypes.
    Musumeci B; Tini G; Biagini E; Merlo M; Calore C; Ammirati E; Zampieri M; Russo D; Grilli G; Santolamazza C; Vio R; Rubino M; Ditaranto R; Del Franco A; Sormani P; Parisi V; Monda E; Francia P; Cipriani A; Limongelli G; Sinagra G; Olivotto I; Boni L; Autore C
    Int J Cardiol; 2024 Apr; 400():131784. PubMed ID: 38242504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study.
    Wang Y; Gao W; Han X; Jiang J; Sandler B; Li X; Zema C
    J Med Econ; 2023; 26(1):1495-1506. PubMed ID: 37902966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of gender on heart failure presentation in non-obstructive hypertrophic cardiomyopathy.
    Jang JH; Shin SH; Beak YS; Ko KY; Kwon SW; Park SD; Woo SI; Kim DH; Kwan J
    Heart Vessels; 2020 Feb; 35(2):214-222. PubMed ID: 31482215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy.
    Maron BJ; Rowin EJ; Udelson JE; Maron MS
    JACC Heart Fail; 2018 May; 6(5):353-363. PubMed ID: 29655822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy.
    Magri D; Agostoni P; Sinagra G; Re F; Correale M; Limongelli G; Zachara E; Mastromarino V; Santolamazza C; Casenghi M; Pacileo G; Valente F; Morosin M; Musumeci B; Pagannone E; Maruotti A; Uguccioni M; Volpe M; Autore C
    Int J Cardiol; 2018 Nov; 271():125-131. PubMed ID: 30087038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pregnancy on the natural history of women with hypertrophic cardiomyopathy.
    Fumagalli C; Zocchi C; Cappelli F; Celata A; Tassetti L; Sasso L; Zampieri M; Argirò A; Marchi A; Targetti M; Berteotti M; Maurizi N; Mori F; Livi P; Baldini K; Tomberli A; Girolami F; Favilli S; Mecacci F; Olivotto I
    Eur J Prev Cardiol; 2024 Jan; 31(1):3-10. PubMed ID: 37531614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue Doppler imaging and prognosis in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy.
    Kitaoka H; Kubo T; Hayashi K; Yamasaki N; Matsumura Y; Furuno T; Doi YL
    Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):544-9. PubMed ID: 23060455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left atrial dysfunction as marker of poor outcome in patients with hypertrophic cardiomyopathy.
    Essayagh B; Resseguier N; Michel N; Casalta AC; Renard S; Donghi V; Carbone A; Piazzai C; Ambrosi P; Levy F; Martel H; Gérard H; Avierinos JF; N'Guyen K; Habib G
    Arch Cardiovasc Dis; 2021 Feb; 114(2):96-104. PubMed ID: 33039326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy.
    Olivotto I; Maron BJ; Tomberli B; Appelbaum E; Salton C; Haas TS; Gibson CM; Nistri S; Servettini E; Chan RH; Udelson JE; Lesser JR; Cecchi F; Manning WJ; Maron MS
    J Am Coll Cardiol; 2013 Jul; 62(5):449-57. PubMed ID: 23643593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy.
    Hamada T; Kubo T; Kitaoka H; Hirota T; Hoshikawa E; Hayato K; Shimizu Y; Okawa M; Yamasaki N; Matsumura Y; Yabe T; Takata J; Doi YL
    Clin Cardiol; 2010 Jul; 33(7):E24-8. PubMed ID: 20641106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes.
    Desai MY; Bhonsale A; Patel P; Naji P; Smedira NG; Thamilarasan M; Lytle BW; Lever HM
    JACC Cardiovasc Imaging; 2014 Jan; 7(1):26-36. PubMed ID: 24290569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global longitudinal strain is associated with heart failure outcomes in hypertrophic cardiomyopathy.
    Reant P; Mirabel M; Lloyd G; Peyrou J; Lopez Ayala JM; Dickie S; Bulluck H; Captur G; Rosmini S; Guttmann O; Demetrescu C; Pantazis A; Tome-Esteban M; Moon JC; Lafitte S; McKenna WJ
    Heart; 2016 May; 102(10):741-7. PubMed ID: 26857213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy.
    Fananapazir L; Epstein ND; Curiel RV; Panza JA; Tripodi D; McAreavey D
    Circulation; 1994 Dec; 90(6):2731-42. PubMed ID: 7994815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of Doppler Tissue Imaging Parameters With Heart Failure Progression in Hypertrophic Cardiomyopathy.
    Kalra A; Harris KM; Maron BA; Maron MS; Garberich RF; Haas TS; Lesser JR; Maron BJ
    Am J Cardiol; 2016 Jun; 117(11):1808-14. PubMed ID: 27089980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the development of adverse cardiac events in patients with hypertrophic cardiomyopathy using machine learning.
    Kochav SM; Raita Y; Fifer MA; Takayama H; Ginns J; Maurer MS; Reilly MP; Hasegawa K; Shimada YJ
    Int J Cardiol; 2021 Mar; 327():117-124. PubMed ID: 33181159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison Between Heart Failure Without Left Ventricular Systolic Dysfunction and Progression to End-Stage in Hypertrophic Cardiomyopathy.
    Nakagawa S; Okada A; Irie Y; Moriuchi K; Amano M; Amaki M; Kanzaki H; Kusano K; Noguchi T; Kitai T; Izumi C
    Circ J; 2024 Jun; ():. PubMed ID: 38910134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiomics from Cardiovascular MR Cine Images for Identifying Patients with Hypertrophic Cardiomyopathy at High Risk for Heart Failure.
    Zhang H; Zhao L; Wang H; Yi Y; Hui K; Zhang C; Ma X
    Radiol Cardiothorac Imaging; 2024 Feb; 6(1):e230323. PubMed ID: 38385758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of future onset of atrial fibrillation in hypertrophic cardiomyopathy.
    Cochet H; Morlon L; Vergé MP; Salel M; Camaioni C; Reynaud A; Peyrou J; Ritter P; Jais P; Laurent F; Lafitte S; Montaudon M; Réant P
    Arch Cardiovasc Dis; 2018 Oct; 111(10):591-600. PubMed ID: 29884599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.